Navigation Links
OptiNose presents data on highly effective migraine treatment
Date:6/28/2008

BOSTON, MA Saturday June 28, 2008 OptiNose announced today that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

Headache relief was achieved in 74.3% and 83.8% of patients at 60 minutes and 120 minutes after administration, respectively, and 48.6% of patients remained pain free after 48 hours. The results were statistically significant when compared to the study's placebo group. The study also confirmed earlier Phase I results. In the Phase I study, the OptiNose powder nasal drug delivery device achieved the maximum sumatriptan concentration in the blood at a median time of 20 minutes after administration. This result was comparable to injections and much faster than other intranasal delivery technologies.

"We are excited to develop this new treatment for the approximately 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device combination will offer patients a much-needed alternative to existing, slower-acting nasal inhalers and tablets and painful injections."

The user feedback from patients who participated in the study was also very encouraging. "The majority of the migraine patients found the device to be both comfortable and easy to use." said Dr Djupesland. "We believe that we can offer a unique therapy for migraine sufferers, combining fast relief, low side effects and high user compliance."

Unlike traditional nasal delivery devices, the unique design of the OptiNose device ensures that drug is delivered to target sites throughout the entire nasal cavity, achieving optimal dose delivery while avoiding the risk of drug deposition to the lungs.


'/>"/>

Contact: Per Djupesland, M.D., Ph.D.
+474-809-0610
OptiNose
Source:Eurekalert

Related medicine news :

1. International Association for Dental Research presents awards and fellowships
2. MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alexs Lemonade Stand Foundation
3. Journal STEM CELLS Presents 3rd Annual Young Investigator Award at International Stem Cell Symposium
4. The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
7. The febit science lounge presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
8. American College of Rheumatology presents recommendations for rheumatoid arthritis therapy
9. Childrens Health and Fitness To Be Focus of ING Presents Marc Anthony Juntos en Concierto Series
10. Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study
11. Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology: